临床试验/NCT02505776

NCT02505776已完成不适用

Safety and Patient Satisfaction With GLASH VISTA™ (Bimatoprost 0.03%) in the Treatment of Eyelash Hypotrichosis in Japan

Allergan0 个研究点目标入组 1,699 人开始时间: 2014年12月8日最近更新: 2018年8月14日

适应症

干预措施

试验速览

阶段: 不适用
状态: 已完成
发起方: Allergan
入组人数: 1,699
主要终点: Change from Baseline in Patient Satisfaction with Eyelashes As Measured by the 3-Item Patient Eyelash Satisfaction Survey

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者记录与标识符相似试验

研究概览

简要总结

This is a post-marketing surveillance study in Japan that will evaluate the safety and patient satisfaction with GLASH VISTA™ (bimatoprost cutaneous solution 0.03%) in the treatment of hypotrichosis of the eyelashes.

研究设计

研究类型: Observational
观察模型: Cohort
时间视角: Prospective

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Patients who have been prescribed GLASH VISTA™ in clinical settings and filled at least one prescription for GLASH VISTA™.

排除标准

未提供

研究组 & 干预措施

GLASH VISTA™

Patients with eyelash hypotrichosis prescribed bimatoprost cutaneous solution 0.03% (GLASH VISTA™) as per local standard of care in clinical practice.

干预措施: Bimatoprost cutaneous solution 0.03% (Drug)

结局指标

主要结局

Change from Baseline in Patient Satisfaction with Eyelashes As Measured by the 3-Item Patient Eyelash Satisfaction Survey

时间窗: Baseline, Month 12

Number of Participants With Adverse Events

时间窗: Up to 12 Months

次要结局

未报告次要终点

研究者

发起方

Allergan

申办方类型

Industry

责任方

Sponsor

相似试验

已完成

不适用

Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid ArthritisRheumatoid Arthritis (RA)

NCT03971253Astellas Pharma Inc3,000

已完成

不适用

PMS Study Ultravist-IMAGE, IoproMide (UltrAvist) to Gain Further Information on Tolerability and Safety in X-ray ExaminationDiagnostic Imaging

NCT00876083Bayer44,920

已完成

不适用

PMCF to Assess Real-life Usage Effectiveness, Safety and Patient Satisfaction of a Range of Hypertonic Seawater-based Decongestant Nasal SpraysURTIAllergic Rhinitis

NCT06104332Laboratoire de la Mer534

已完成

不适用

Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic LeukemiaChronic Lymphocytic LeukemiaFollicular Lymphoma

NCT03374137Hoffmann-La Roche55

招募中

不适用

Results of Patients With Glaucoma Undergoing Minimally Invasive Glaucoma Surgery in Conjunction With Cataract SurgeryGlaucoma, Open-AngleCataract

NCT05624398Vold Vision P.L.L.C25